Related Experiment Videos
Substance P antagonists: the next breakthrough in treating depression?
Journal of Clinical Pharmacy and Therapeutics
|January 29, 2000
Summary
Substance P and its receptor NK1 may play a role in depression. NK1 receptor antagonists show potential as a novel antidepressant therapy, with clinical trials ongoing to confirm efficacy and safety.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- The neuropeptide substance P is implicated in depression pathogenesis.
- NK1 receptor antagonists have demonstrated antidepressant-like effects in animal models.
Purpose of the Study:
- To investigate the potential of NK1 (substance P) receptor antagonists as a novel therapeutic target for depression.
- To evaluate the clinical efficacy and tolerability of NK1 antagonism for antidepressant activity.
Main Methods:
- Review of preclinical evidence for substance P and NK1 receptor involvement in depression.
- Analysis of results from early-phase clinical trials of NK1 receptor antagonists.
Main Results:
- Preclinical studies suggest NK1 receptor antagonism has antidepressant-like actions.
- An initial clinical trial of an NK1 antagonist yielded promising results.
Conclusions:
- NK1 (substance P) receptor antagonism represents a potential novel mechanism for antidepressant therapy.
- Further clinical trials are necessary to establish the efficacy and safety of NK1 antagonists as standalone or adjunctive treatments for depression.